Chicago Partners Investment Group’s Vertex Pharmaceuticals VRTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$512K Buy
1,170
+303
+35% +$141K 0.01% 874
2025
Q4
$406K Sell
867
-140
-14% -$60.3K 0.01% 882
2025
Q3
$425K Sell
1,007
-117
-10% -$48.9K 0.01% 785
2025
Q2
$536K Buy
1,124
+176
+19% +$81.1K 0.02% 570
2025
Q1
$412K Buy
948
+141
+17% +$65.7K 0.01% 582
2024
Q4
$333K Buy
807
+332
+70% +$154K 0.01% 623
2024
Q3
$223K Buy
475
+29
+7% +$13.9K 0.01% 717
2024
Q2
$224K Buy
+446
New +$194K 0.01% 690
2018
Q4
Sell
-32
Closed -$5K 909
2018
Q3
$5K Buy
+32
New +$5.7K ﹤0.01% 926

Other funds holding VRTX

Chicago Partners Investment Group's VRTX Position: Q1 2026 in Review

Chicago Partners Investment Group increased its Vertex Pharmaceuticals (VRTX) stake by 35% in Q1 2026, buying an estimated $141K and bringing the position to 1,170 shares worth $512K. The position accounts for 0.01% of the portfolio, ranked #874.

Chicago Partners Investment Group first reported a position in VRTX in Q3 2018 and has held it in 9 quarters since. The position peaked at $536K in Q2 2025. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • Chicago Partners Investment Group held 1,170 shares of Vertex Pharmaceuticals worth $512K as of Q1 2026.
  • Chicago Partners Investment Group bought 303 Vertex Pharmaceuticals shares in Q1 2026, an estimated $141K.
  • Vertex Pharmaceuticals made up 0.01% of Chicago Partners Investment Group's portfolio in Q1 2026, its #874 holding.
  • Chicago Partners Investment Group first reported a position in Vertex Pharmaceuticals in Q3 2018 and has held it in 9 quarters since.
  • Chicago Partners Investment Group's Vertex Pharmaceuticals position peaked at $536K in Q2 2025.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Chicago Partners Investment Group's 13F filing for Q1 2026, filed 4 May 2026.